Trial Profile

A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ficlatuzumab (Primary) ; Erlotinib
Indications Hodgkin's disease; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors AVEO Oncology

23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
19 Mar 2013 Planned end date changed from 1 Mar 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
11 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com